info @diagnos.com

Discover our strategy

Stay Ahead with Diagnos Updates

Subscribe to our newsletter for company updates!

insert team picture or technology picture here

Why Investors Choose Diagnos

AI-Driven Early Disease Detection
Diagnos’ FDA-filed deep-learning platform detects eye and systemic diseases before symptoms appear, with accuracy beyond human specialists
Commercial Momentum
Multi-year agreements signed with EssilorLuxottica and NewLook Vision, giving Diagnos direct access to thousands of optical retail locations worldwide
Massive Market Opportunity
The $11 billion retinal-AI market is expanding fast as aging populations and specialist shortages drive adoption of automated screening tools
Positioned for Global Scale-Up
Regulatory filings submitted in the U.S., Canada, and Saudi Arabia, with distributors ready to scale and 500,000 patients already tested

Ready to Learn More?

Join a growing base of investors who engage with Diagnos.
Connect with our team or access our latest investor materials today.

Disclaimer

All investing is subject to risk, including the possible loss of the money you invest.

These statements should not be construed as, (i) an offer to sell or a solicitation of an offer to buy any security, or (ii) investment, tax, legal, or other advice. Any such offer or solicitation will be made only by means of an offering document that meets all applicable legal requirements.

Statements contained herein that are not historical facts, including statements regarding objectives, strategies, and performance targets, may constitute forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in such statements. Past performance is not necessarily indicative of, and cannot be relied upon as a guarantee of, future results. Investors should consult their own advisors with respect to any investment decision.